These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7583490)

  • 1. Cost-benefits of new drugs.
    Daniel DG; Moseley C; Rosenfield S; Wolf S; Nawroz S
    Psychiatr Serv; 1995 Aug; 46(8):835-6. PubMed ID: 7583490
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing a drug's cost-benefits.
    Raleigh F
    Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
    Annemans L
    Pharmacoeconomics; 2005; 23 Suppl 1():1-2. PubMed ID: 16416757
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone.
    Aronson SM
    Clin Ther; 1997; 19(1):139-47; discussion 126-7. PubMed ID: 9083716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal-emergent respiratory dyskinesia with risperidone treated with clozapine.
    Mendhekar DN; Inamdar A
    J Neuropsychiatry Clin Neurosci; 2010; 22(2):E24. PubMed ID: 20463136
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-benefits of risperidone.
    Bilsker D
    Psychiatr Serv; 1996 Mar; 47(3):309-10. PubMed ID: 8820560
    [No Abstract]   [Full Text] [Related]  

  • 8. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia.
    Amin S
    Hosp Med; 1999 Jun; 60(6):410-3. PubMed ID: 10492711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone-induced tardive dyskinesia.
    Hong KS; Cheong SS; Woo JM; Kim E
    Am J Psychiatry; 1999 Aug; 156(8):1290. PubMed ID: 10450277
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacoeconomic aspects of the use of rispolept in therapy of patients with psychoses].
    Iakovlev VA; Dorovskikh IV; Belinskiĭ AV; Shcherbakov DV; Zhbrykunov VL; Martyniuk IuL
    Voen Med Zh; 2001 Mar; 322(3):54-7. PubMed ID: 11544710
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost effectiveness of long-acting risperidone in Sweden.
    Hensen M; Heeg B; Löthgren M; van Hout B
    Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone-induced tardive dyskinesia.
    Silberbauer C
    Pharmacopsychiatry; 1998 Mar; 31(2):68-9. PubMed ID: 9562211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues.
    Basu A
    Schizophr Res; 2004 Dec; 71(2-3):445-62. PubMed ID: 15474916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan.
    Chang HC; Tang CH; Tsai SJ; Yen FC; Su KP
    J Clin Psychiatry; 2009 Jan; 70(1):141. PubMed ID: 19238691
    [No Abstract]   [Full Text] [Related]  

  • 16. Antipsychotic drugs and schizophrenia.
    Gupta N; Basu D
    N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422018
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
    Keith S
    Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Have the serotonin-dopamine antagonists rendered traditional antipsychotic agents obsolete?
    Goff DC
    Harv Rev Psychiatry; 1995; 3(2):101-3. PubMed ID: 9384935
    [No Abstract]   [Full Text] [Related]  

  • 19. Risperidone-induced tardive dyskinesia in first-episode psychotic patients.
    Campbell M
    J Clin Psychopharmacol; 1999 Jun; 19(3):276-7. PubMed ID: 10350038
    [No Abstract]   [Full Text] [Related]  

  • 20. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
    Carter CS; Mulsant BH; Sweet RA; Maxwell RA; Coley K; Ganguli R; Branch R
    Psychopharmacol Bull; 1995; 31(4):719-25. PubMed ID: 8851645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.